Insulin manufacturers are expanding insulin affordability options for patients with diabetes during the coronavirus pandemic.
Novo Nordisk has fired the first “shot heard around the health care world.”
As the price of insulin has skyrocketed, patients with diabetes are struggling to pay for their medication.
Due to ongoing insulin affordability challenges, Novo Nordisk is offering new cost assistance options for patients with diabetes.
Results at ASHP 2019 suggest potential for administration errors without proper guidance.
Previously approved for IV infusion.
As people with type 2 diabetes age, the risks of insulin use can outweigh its benefits, creating the need for increased provider and patient education.
FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.
While pharmacy benefit managers were grilled about insulin prices at Congressional hearings last week, some PBMs, insurers and pharma makers are already lowering insulin costs.
Eli Lilly creates generic Humalog priced 50% lower